Immedica welcomes Benjamin Owens as Head of Corporate Development

Stockholm, November 11, 2024 – Immedica is pleased to announce that Benjamin Owens, Ph.D. has joined the company as Executive Vice President and Head of Corporate Development. Ben brings 15 years of experience in the life sciences field including roles in business development and operational leadership across both R&D- and commercial-stage companies.

Benjamin has a track record of successfully sourcing, leading and executing strategic transactions, including M&A, cross-border licensing, financing and company formation. With broad expertise in areas ranging from R&D,  clinical development and commercialization to pipeline and intellectual property strategy, he has guided companies from early-stage growth through to successful exit, notably contributing  - as part of the executive team at EUSA Pharma - to building and scaling a commercial stage rare oncology business from start up to over 300 employees globally, with multiple launched rare disease therapeutic products acquired through M&A. He has built a broad global network that spans major pharmaceutical companies, biotech firms, private equity, venture capital, and academic institutions.

“We are thrilled to welcome Ben to the Immedica team,” said Anders Edvell, CEO of Immedica. “Ben’s extensive experience in business development and transaction execution, combined with his scientific background in immunology and entrepreneurial mindset, make him a key asset as we continue to expand our global footprint and drive forward our mission to deliver innovative therapies to patients with rare diseases.”

Benjamin Owens will lead Immedica’s business development efforts globally, guiding the company’s strategy for growth, partnerships, and M&A activities as it continues to strengthen its position in the rare disease therapeutics marketplace. Prior to joining Immedica, Benjamin served as Chief Business Officer and a Board Member at Peptone, where he was instrumental in pivoting the company’s strategy to therapeutics development, working with founders to successfully execute a $40M Series A financing, and subsequently building a 50 FTE R&D organization with an early pipeline of biologic and small molecule assets. Before that, he was VP and Head of Global Business Development at EUSA Pharma, where he led several transformative asset acquisitions and licensing deals, playing a key role in the company's rapid growth and international expansion through to an acquisition by Recordati S.p.A in 2022. Prior to the Pharmaceutical industry, Benjamin had a successful career as an academic at the University of Oxford, with his research and teaching focused on translational immunology and chronic inflammation.

"I am excited to join Immedica at such a pivotal stage in the company’s growth trajectory," said Benjamin Owens. "Immedica has already established itself as a leader in the rare disease space, and I look forward to leveraging my experience to support the company's ambitious goals of bringing novel therapies to underserved patient populations across the world."

In addition, Immedica announces that Håkan Garpenstrand, one of Immedica's founders and its long-serving Head of Business Development, has decided to leave his employment to retire early.

“Håkan has been instrumental in shaping Immedica from its inception, playing a critical role in its growth and success.” said Anders Edvell. “We are deeply grateful for his contributions and wish him the very best in his well-deserved retirement.”

About Immedica
Immedica is a pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Immedica’s capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory, medical affairs and market access, as well as a global distribution network serving patients in more than 50 countries. Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need. Immedica’s therapeutic areas are within genetic & metabolic diseases, hematology & oncology and specialty care.

Immedica was founded in 2018 and employs today around 130 people across Europe, the Middle East and the U.S. The main owners are the investment firms KKR and Impilo.

For more information visit www.immedica.com

Immedica contact:
Linda Holmström
Global Head of Communication
linda.holmstrom@immedica.com
+ 46 708 73 40 95

Immedica Pharma AB
Solnavägen 3H
SE-113 63 Stockholm